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abstract
PURPOSEWe assessed the prognostic/predictive role of primary tumor sidedness and uncommon alterations of
anti–epidermal growth factor receptor (EGFR) primary resistance (primary resistance in RAS and BRAF wild-
type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies [PRESSING] panel) in
patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who were randomly assigned to
panitumumab plus ﬂuorouracil, leucovorin, and oxaliplatin (FOLFOX-4) induction followed by maintenance with
panitumumab with or without ﬂuorouracil (FU) plus leucovorin (LV); Valentino trial (ClinicalTrials.gov identiﬁer:
NCT02476045).
PATIENTS AND METHODS This prespeciﬁed retrospective analysis included 199 evaluable patients with RAS/
BRAFwt. The PRESSING panel included the following: immunohistochemistry (IHC) and in situ hybridization for
HER2/MET ampliﬁcation, IHC with or without RNA sequencing for ALK/ROS1/NTRKs/RET fusions, next-
generation sequencing for HER2/PIK3CAex.20/PTEN/AKT1 and RAS mutations with low mutant allele frac-
tion, and multiplex polymerase chain reaction for microsatellite instability. PRESSING status (any positive
biomarker v all negative) and sidedness were correlated with overall response rate (ORR), progression-free
survival (PFS), and overall survival (OS) in the study population and by treatment arm.
RESULTS Overall, left- and right-sided tumors were 85.4% and 14.6%, respectively, and PRESSING-negative
and -positive tumors were 75.4% and 24.6%, respectively. At a median follow-up of 26 months, inferior
outcomes were consistently observed in right- versus left-sided tumors for ORR (55.2% v 74.1%; P = .037), PFS
(8.4 v 11.5 months; P = .026), and OS (2-year rate: 50.2% v 65.1%; P = .062). Similar results were observed in
the PRESSING-positive versus PRESSING-negative subgroup for ORR (59.2% v 75.3%; P = .030), PFS (7.7 v
12.1months; P, .001), and OS (2-year rate: 48.1% v 68.1%; P = .021). The PFS beneﬁt of FU plus LV added to
panitumumab maintenance, reported in the study, was independent from sidedness and PRESSING status
(interaction for PFS P = .293 and .127, respectively). However, outcomes were extremely poor in patients who
received single-agent panitumumab and had right-sided tumors (median PFS, 7.7 months; 2-year OS, 38.5%)
or PRESSING-positive tumors (median PFS, 7.4 months; 2-year OS, 47.0%).
CONCLUSION The combined assessment of sidedness andmolecular alterations of anti-EGFR primary resistance
identiﬁed a consistent proportion of patients with RAS/BRAF–wt mCRC who had inferior beneﬁt from initial anti-
EGFR–based regimens, particularly after maintenance with single-agent anti-EGFRs.
J Clin Oncol 37:3099-3110. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The decision-making algorithm of the treatment of
patients with metastatic colorectal cancer (mCRC) has
deeply changed in the recent years, and it should now
take into account both clinical and tumor molecu-
lar features. Since the introduction of anti–epidermal
growth factor (EGFR) monoclonal antibodies, the
progressive reﬁnement of the negative selection par-
adigm has led to notable improvements of patients’
outcomes.1 All current guidelines recommend con-
sideration of an anti-EGFR–based ﬁrst-line therapy
after the evaluation of RAS and BRAF mutational
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status in addition to assessment of primary tumor sidedness.2,3
Because of the negative predictive role of RAS and BRAF
mutations and right sidedness, patients with left-sided, RAS
andBRAFwild-typemCRC currently are regarded as optimal
candidates for anti-EGFR agents alone or in combination
with chemotherapy.4-9 However, several gaps in knowledge
about primary resistance to EGFR inhibition exist, and more
negative predictive biomarkers would be clinically useful in
both left- and right-sided primary tumors.
In a recent case-control study in patients with RAS and
BRAF wild-type mCRC treated with single-agent anti-EGFR
therapy,10 we demonstrated the promising negative pre-
dictive impact of a panel of uncommon molecular alter-
ations linked to primary resistance to EGFR inhibition.
This panel, the Primary resistance in RAS and BRAF wild-
type metastatic colorectal cancer patients treated with anti-
EGFR monoclonal antibodies (PRESSING) panel, includes
HER2 ampliﬁcation/activating mutations; MET ampliﬁca-
tion; NTRK/ROS1/ALK/RET rearrangements; PIK3CA exon
20, and PTEN and AKT1 mutations.
Here, we present the results of a prespeciﬁed exploratory
analysis of the Valentino study (ClinicalTrials.gov identiﬁer:
NCT02476045) to investigate the prognostic role of tumor
sidedness and PRESSING panel in patients with RAS and
BRAF wild-type mCRC who were randomly assigned to
maintenance with either single-agent panitumumab or
panitumumab plus ﬂuorouracil and leucovorin (FU + LV)
after a 4-month induction with panitumumab plus ﬂuoro-
uracil, leucovorin, and oxaliplatin (FOLFOX-4).
PATIENTS AND METHODS
Study Population
The Valentino study was a multicenter, randomized, open-
label, phase II trial that investigated the progression-free sur-
vival (PFS) noninferiority of maintenance with single-agent
panitumumab (arm B) versus panitumumab plus FU plus
LV (arm A) after an induction treatment with panitumumab
plus FOLFOX-4 in patients with RAS wild-type mCRC.11 The
trial enrolled 229 patients (armA, n = 117; armB, n =112) and
showed that maintenance with single-agent panitumumab
is inferior to panitumumab plus FU/LV in terms of PFS.
The main inclusion criteria were as follows: histologi-
cally conﬁrmed CRC with RAS (exons 2, 3, and 4 of both
KRAS and NRAS) wild-type status conﬁrmed by ap-
proved methods; an Eastern Cooperative Oncology Group
performance score (ECOG PS) of 0 to 1; no previous
treatment of metastatic disease, unresectable metasta-
ses, measurable, or just-evaluable disease according to
RECIST version 1.1; and availability of baseline tumor
samples centrally collected at the coordinating center
(Fondazione IRCCS Istituto Nazionale dei Tumori). Pa-
tients were excluded if they had experienced relapse
during adjuvant oxaliplatin-based chemotherapy or within
12 months from its completion (or within 6 months for
adjuvant ﬂuoropyrimidine monotherapy) or in case of
notable comorbidities.
For this exploratory analysis, we selected all those patients
enrolled in the trial with at least one radiologic disease
assessment and with tumor tissue specimens obtained
before enrollment and available for a complete molecular
analysis, including PRESSING panel and RAS/BRAF mu-
tational status centrally determined at the coordinating
center via next-generation sequencing (NGS). Institutional
review board and ethics committee approvals were ob-
tained from all participating centers. All of the patients
provided written informed consent before any study-related
procedures occurred.
Molecular Analyses
The PRESSING panel analysis included the following
genomic alterations, as previously reported: HER2
ampliﬁcation/activating mutations; MET ampliﬁcation;
NTRK/ROS1/ALK/RET rearrangements; PIK3CA exon 20
mutations, PTEN inactivating mutations, and AKT1 mu-
tations.10 Brieﬂy, immunohistochemistry (IHC) for HER2/
MET and dual-color silver in situ hybridization for both
genes were performed. IHC analyses for ALK/ROS1/
panTRK/RET were performed as the screening method for
actionable gene fusions; in all samples with evidence of IHC
staining of any intensity/extension, whole-transcriptome
shotgun sequencing (RNA-seq) was performed to con-
ﬁrm the presence of speciﬁc rearrangements. Oncogenic
mutations in the hotspot regions of 50 cancer-related genes
(Cancer Hotspot Panel v2; ThermoFisher Scientiﬁc, Wal-
tham,MA), includingHER2 and PIK3CA/PTEN/AKT1, were
assessed bymeans of targeted NGS through the Ion Torrent
Personal Genome platform (ThermoFisher Scientiﬁc). In
addition, by means of targeted NGS, RAS and BRAF
mutational status was centrally reassessed with deeper
coverage, and the fractional abundance of BRAF and RAS
mutant allele fractions (MAFs) was reported after correction
for tumor cellularity.12
On the basis of recent data onmicrosatellite instability (MSI)
as a poor predictive factor in patients who received anti-
EGFR–based ﬁrst-line therapy,13 multiplex polymerase-
chain reaction (PCR) was performed to evaluate MSI status.
For additional details, see the Appendix (online only).
Statistical Analysis
PFS was deﬁned as the interval from random assignment
to ﬁrst objective documentation of progressive disease (PD)
or death as a result of any cause, whichever occurred ﬁrst
(censored at last follow-up for patients alive and without
PD). Overall survival (OS) was the interval from random
assignment to death as a result of any cause (censored at
last follow-up for patients alive). Overall response rate
(ORR) was deﬁned as the proportion of patients who
achieved a complete (CR) or partial response (PR). Bi-
nomial two-sided 95% CIs were calculated for ORR. Sur-
vival analyses were performed using the Kaplan-Meier
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method and the Cox proportional-hazards model. Variables
with a P value of , .1 at univariable analysis were entered
into the multivariable models. An interaction term was
included in the statistical models when subgroup analyses
were performed. Median follow-up was calculated by the
reverse Kaplan-Meier approach. The x2 test, the Fisher
exact test, or the Mann-Whitney U test was used, as ap-
propriate, to evaluate the association between patient
baseline characteristics and tumor sidedness or PRESSING
panel status. The x2 test or Fisher exact test was used, as
appropriate, to assess the association between sidedness
and/or PRESSING panel status with ORR. All tests were two
sided at a of 5%. The analyses were carried out using R
(version 3.5.0) and R Studio (version 1.1.447) and the
survival, survminer, and epitools packages.
RESULTS
Baseline Characteristics
A total of 199 (87%) of the 229 enrolled in the Valentino
study were eligible for this prespeciﬁed exploratory analysis.
The CONSORT diagram of the study is illustrated in Ap-
pendix Figure A1 (online only).
Baseline patients and disease characteristics are listed in
Table 1. Overall, 52.3% and 47.7% patients were treated in
arms A and B, respectively. Left- and right-sided tumors
accounted for 170 (85.4%) and 29 (14.6%) patient cases,
and the PRESSING panel was negative in 150 (75.4%)
patients and positive in 49 (24.6%) patients.
The incidence of the singular molecular alterations in-
cluded in the PRESSING panel is illustrated in Figure 1 and
listed in Appendix Table A1 (online only). Notably, am-
pliﬁcations of HER2 and MET genes were present in nine
patients (4.5%) and three patients (1.5%), respectively.
Gene fusions were reported in ﬁve patients (2.5%); spe-
ciﬁcally, three were rearrangements of RET, one was of
ALK, and one was of NTRK. Mutations of PI3KCA exon 20
were found in 10 patients (5.0%); of PTEN, in six (3.0%);
and of AKT1, in two (1%). RAS mutations with low MAF
(, 5%) occurred in 15 patients (7.5%). Overall, MSI-high
status was detected in ﬁve patients (2.5%), of whom two
(40%) had disease associated with speciﬁc PRESSING
alterations and only one (20%) had right sidedness.
Regarding the associations between baseline character-
istics and tumor sidedness or PRESSING panel, no sig-
niﬁcant associations were observed except for older age in
right-sided tumors (P = .02). A borderline correlation was
observed between primary tumor sidedness and PRESSING
panel, with a higher rate of PRESSING positivity in right-
sided tumors (37.9%) versus left-sided ones (22.3%; P =
.07; Table 1).
At the time of this analysis (cutoff on March 30, 2019), the
median follow-up was 26 months (95% CI, 24.6 to 29
months). A total of 167 disease progressions and 85 deaths
occurred. Appendix Figures A2A and A2B (online only)
depict, respectively, the PFS (median, 11.1 months) and
OS (median, 30.7 months; 2-year OS rate, 63%) curves in
the whole-study population.
Response Analyses According to Sidedness and
PRESSING Panel
The ORR in the study population was 75.5% (95% CI,
68.4% to 81.5%). According to sidedness, the ORR was
74.1% (95% CI, 66.9% to 80.5%) and 55.2% (95% CI,
35.7% to 73.6%) in left- and right-sided tumors, re-
spectively (odds ratio [OR], 0.43; 95% CI, 0.19 to 0.99; P =
.037; Appendix Fig A3A, online only). In PRESSING pan-
el–negative and –positive tumors, the ORR was 75.3%
(95% CI, 67.6% to 82.0%) and 59.2% (95% CI, 44.2% to
73.0%), respectively (OR, 0.48; 95% CI, 0.24 to 0.95; P =
.030; Appendix Fig A3B). The ORR for patients with
PRESSING-positive versus -negative tumors was 77.3%
versus 63.2% (OR, 0.51; 95% CI, 0.23 to 1.12; P = .080)
in the left-sided subgroup and was 45.6% versus 61.1%
(OR, 0.55; 95% CI, 0.11 to 2.57; P = .466) in the right-
sided subgroup (Appendix Fig A3C). Appendix Table A2
(online only) provides information on sidedness, speciﬁc
PRESSING panel alterations, and RECIST response at in-
dividual patient level. Appendix Table A3 (online only) and
Appendix Figure A4 (online only) summarize the results in
terms of depth of response and duration of response, re-
spectively, according to sidedness, PRESSING panel sta-
tus, or both.
Prognostic Analyses According to Sidedness and
PRESSING Panel
The PFS was lower in the right-sided versus left-sided
subgroup (median PFS, 8.4 v 11.5 months; hazard ratio
[HR], 1.60; 95% CI, 1.06 to 2.42; P = .026; Fig 2A), as was
OS (2-year OS, 50.2% v 65.1%; HR, 1.71; 95% CI, 0.97 to
2.99; P = .062; Fig 2B). In parallel, PFS was lower in the
PRESSING-positive versus PRESSING-negative subgroup
(median PFS, 7.7 v 12.1months; HR, 1.90; 95%CI, 1.35 to
2.67; P , .001; Fig 2C) as well as OS (2-year OS, 48.1% v
68.1%; HR, 1.71, 95% CI, 1.09 to 2.69; P = .021; Fig 2D).
The median PFS of patients with PRESSING-positive
versus PRESSING-negative tumors was 7.8 versus
13.2 months (HR, 2.01; 95% CI, 1.37 to 2.94; P , .001)
in the left-sided subgroup, and it was 7.7 versus 8.6
months (HR, 1.40; 95% CI, 0.64 to 3.06; P = .399) in the
right-sided subgroup (Fig 2E). Consistent results were
observed in terms of OS: the 2-year OS of patients with
PRESSING-positive versus -negative tumors was 49.9%
versus 69.7% (HR, 1.78; 95% CI, 1.08 to 2.95; P = .025)
in the left-sided subgroup and was 40.9% versus 55.6%
(HR, 1.16; 95% CI, 0.41 to 3.25; P = .786) in the right-
sided subgroup (Fig 2F). Finally, PFS was lower in the
MSI-high versus microsatellite-stable subgroup (median
PFS, 4.1 v 11.1 months; HR, 3.03; 95% CI, 1.24 to 7.42;
P = .015; Appendix Fig A5A, online only), whereas OS
was similar in the two subgroups (2-year OS, 60.0% v
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62.9%; HR, 1.23; 95% CI, 0.38 to 3.92; P = .732; Ap-
pendix Fig A5B, online only).
In the univariable analysis for PFS, ECOG PS, number
of metastatic sites (one v more than one), MSI status,
primary tumor sidedness, and PRESSING panel were
significantly associated with PFS; however, only ECOG PS
(0 v 1), number of metastatic sites (one v more than
one), and PRESSING panel conﬁrmed their prognostic
value in the multivariable model, whereas sidedness lost
its signiﬁcance. Similarly, in the univariable analysis for
OS, ECOG PS, prior adjuvant treatment, number of met-
astatic sites, and PRESSING panel were signiﬁcantly
associated with OS; ECOG PS, prior adjuvant treatment,
and PRESSING panel were conﬁrmed in the multivariable
model. In particular, the strongest association with poor
PFS and OS was reported in the multivariable models for
PRESSING-positive tumors (P , .001 and P = .007, re-
spectively; Table 2).
TABLE 1. Baseline Characteristics in the Overall Population and According to Sidedness PRESSING Panel Status
Characteristic
Data for All Patients
(N = 199)
Data by Sidedness
P
Data by PRESSING Status
P
Left
(n = 170)
Right
(n = 29)
Negative
(n = 150)
Positive
(n = 49)
Median age, years (IQR) 62 (54-69) 62 (54-68) 68 (61-71) .021 63 (55-69) 61 (52-69) .389
Sex .342 .602
Female 67 (33.7) 55 (32.3) 12 (41.4) 52 (34.7) 15 (30.6)
Male 132 (66.3) 115 (67.7) 17 (58.6) 98 (65.3) 34 (69.4)
ECOG PS .300 .468
0 146 (73.4) 127 (74.7) 19 (65.5) 112 (74.7) 34 (69.4)
1 53 (26.6) 43 (25.3) 10 (34.5) 38 (25.3) 15 (30.6)
Prior adjuvant treatment .138 .107
Yes 27 (13.6) 26 (15.3) 1 (3.4) 17 (11.3) 10 (20.4)
No 172 (86.4) 144 (84.7) 28 (96.6) 133 (88.7) 39 (79.6)
Primary tumor resected .495 .993
Yes 126 (63.3) 106 (62.4) 20 (69.0) 95 (63.3) 31 (63.3)
No 73 (36.7) 64 (37.6) 9 (31.0) 55 (36.7) 18 (36.7)
Liver-limited disease .07 .394
Yes 71 (35.7) 65 (38.2) 6 (20.7) 56 (37.3) 15 (30.6)
No 128 (64.3) 105 (61.8) 23 (79.3) 94 (62.7) 34 (69.4)
Synchronous metastases .124 .060
Yes 157 (78.9) 131 (77.1) 26 (89.7) 123 (82.0) 34 (69.4)
No 42 (21.1) 39 (22.9) 3 (10.3) 27 (18.0) 15 (30.6)
No. of metastatic sites .634 .270
1 111 (55.8) 96 (56.5) 15 (51.7) 87 (58.0) 24 (49.0)
. 1 88 (44.2) 74 (43.5) 14 (48.3) 63 (42.0) 25 (51.0)
Treatment arm .734 .841
Panitumumab 95 (47.7) 82 (48.2) 13 (44.8) 71 (47.3) 24 (49.0)
Panitumumab plus FU + LV 104 (52.3) 88 (51.8) 16 (55.2) 79 (52.7) 25 (51.0)
Primary tumor sidedness — .072
Left 170 (85.4) — — 132 (88.0) 38 (77.6)
Right 29 (14.6) — — 18 (12.0) 11 (22.4)
PRESSING panel .072 —
Negative 150 (75.4) 132 (77.7) 18 (62.1) — —
Positive 49 (24.6) 38 (22.3) 11 (37.9) — —
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FU + LV, ﬂuorouracil plus leucovorin; IQR, interquartile
range; PRESSING, primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal
antibodies.
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Predictive Analyses According to Sidedness and
PRESSING Panel
Results about the predictive role of sidedness, PRESSING
panel status, or both according to the two treatment arms
are summarized in Table 3. Primary tumor sidedness was
not signiﬁcantly associated with differential effect of the two
maintenance arms in terms of PFS and OS (P for interaction =
.293 and .068, respectively), although the PFS and OS
beneﬁts from maintenance treatment with panitumumab
plus FU plus LV were higher among patients with right-
than with left-sided tumors (Figs 3A and 3B). Similar results
were observed with regard to the predictive effect of the
PRESSING panel for both PFS and OS (P for interaction =
.127 and .450, respectively), although the PFS beneﬁt from
addition of FU plus LV to panitumumab in the maintenance
setting was clearly superior in PRESSING-positive tumors
(Figs 3C and 3D). Consistent results were found when the
predictive role of the PRESSING panel was analyzed with
regard to maintenance treatment arm in the subgroup of
patients with left-sided tumors (Appendix Table A4, online
only; Appendix Fig A6, online only), whereas the sample
size was too limited to perform such analyses in the sub-
group of patients with right-sided tumors.
DISCUSSION
In a previous prospective, case-control study, we showed
the potential negative predictive role of the PRESSING
panel, including several genomic alterations selected on
the basis of the most robust and biologically sound bio-
markers of primary resistance to anti-EGFRs beyond RAS
and BRAF mutational status and primary tumor sided-
ness.10 In this prespeciﬁed exploratory analysis of the
Valentino study, we investigated the potential prognostic
and predictive role of primary tumor sidedness and
PRESSING panel in patients with RAS and BRAF wild-type
mCRC who were randomly assigned to panitumumab plus
FOLFOX-4 followed by maintenance with either single-
agent panitumumab or panitumumab plus FU plus LV.
We reported that a negative hyperselection beyond RAS
and BRAF, obtained through the accurate analysis of
multiple and less frequent genomic alterations included in
the PRESSING panel, combined with the evaluation of
tumor sidedness, allowed better prediction of the outcomes
in this study population. In particular, patients with left-
sided and PRESSING-negative tumors achieved clearly
better outcomes in terms of both PFS and OS, and FU plus
LV–based maintenance treatment had a positive PFS im-
pact also in this patient subgroup.
Of note, no signiﬁcant associations between baseline char-
acteristics and tumor sidedness or PRESSING panel
were observed (except for older age in right-sided tumors).
As expected, the association between sidedness and
PRESSING panel positivity was due to the enrichment of
resistance alterations (except HER2 ampliﬁcation) in right-
sided tumors.10,14-16 This correlation may have failed to
achieve statistical signiﬁcance because of the low number
of right-sided tumors in the study population. However, even
if primary tumor sidedness may be a surrogate marker for
the heterogeneous molecular proﬁle of mCRC, primary re-
sistance to anti-EGFRs displayed by right-sided cancers is
not fully explained by the well-known and biologically vali-
dated genomic alterations included in the PRESSING panel
and may be linked to speciﬁc gene expression proﬁles or
miRNAs, such as miR-31-3p.17,18
The results of this study were internally consistent, because
ORR, PFS, and OS were all decreased in right-sided tumors
compared with left-sided ones and in PRESSING-positive
with respect to -negative ones. In the multivariable model,
the PRESSING panel was the strongest prognostic factor
not only in terms of PFS but also with regard to OS.
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FIG 2. Prognostic analysis according to tumor sidedness and primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients
treated with anti-EGFRmonoclonal antibodies (PRESSING) panel status: Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall
survival (OS) in patients stratiﬁed according to tumor sidedness; (C) PFS and (D) OS according to PRESSING panel status; and (E) PFS and (F) OS
according to the combined analysis. HR, hazard ratio; NA, not assessable; ref, reference.
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TABLE 2. Univariable and Multivariable Cox Proportional Hazard Regression Models for PFS and OS
Variable
PFS OS
Univariable
Analysis
Multivariable
Model
Univariable
Analysis
Multivariable
Model
HR
(95% CI) P
HR
(95% CI) P
HR
(95% CI) P
HR
(95% CI) P
Median age, years (IQR) 0.99 (0.98-1.01) .686 1.02 (0.99-1.04) .124
Sex .676 .738
Female Reference Reference
Male 0.93 (0.67 to 1.29) 1.08 (0.68 to 1.71)
ECOG PS .033 .036 .0003 , .001
0 Reference Reference Reference Reference
1 1.44 (1.03 to 2.03) 1.45 (1.03 to 2.05) 2.25 (1.45 to 3.48) 2.32 (1.49 to 3.60)
Prior adjuvant treatment .072 .071 .011 .003
No Reference Reference Reference Reference
Yes 0.66 (0.42 to 1.04) 0.66 (0.42 to 1.04) 0.34 (0.15 to 0.77) 2.27 (0.11 to 0.64)
Primary tumor resected .399 .419
No Reference Reference
Yes 0.87 (0.64 to 1.20) 0.84 (0.54 to 1.29)
Liver-limited disease .274 .254
No Reference Reference
Yes 0.84 (0.61 to 1.15) 0.77 (0.49 to 1.21)
Synchronous metastases .316 .157
No Reference Reference
Yes 1.21 (0.84 to 1.74) 1.50 (0.86 to 2.62)
No. of metastatic sites .003 .005 .036 .055
1 Reference Reference Reference Reference
. 1 1.59 (1.17 to 2.16) 1.58 (1.15 to 2.17) 1.58 (1.03 to 2.42) 1.53 (0.99 to 2.35)
Treatment arm .062 .013 .878
Panitumumab
plus FU + LV
Reference Reference Reference
Panitumumab 1.34 (0.99 to 1.82) 1.50 (1.09 to 2.06) 0.97 (0.63 to 1.48)
MSI status .015 .626 .732
MSS Reference Reference Reference
MSI high 3.03 (1.24 to 7.42) 1.28 (0.47 to 3.47) 1.23 (0.38 to 3.92)
Primary tumor sidedness .026 .175 .062 .214
Left Reference Reference Reference Reference
Right 1.60 (1.06 to 2.42) 1.36 (0.87 to 2.13) 1.71 (0.97 to 2.99) 1.44 (0.81 to 2.55)
PRESSING panel , .001 , .001 .021 .007
Negative Reference Reference Reference Reference
Positive 1.90 (1.35 to 2.67) 2.03 (1.41 to 2.92) 1.71 (1.09 to 2.69) 1.89 (1.19 to 3.01)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FU + LV, ﬂuorouracil plus leucovorin; HR, hazard ratio; IQR,
interquartile range; MSI, microsatellite instability; MSS, microsatellite stable; OS, overall survival; PFS, progression-free survival; PRESSING, primary
resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
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Conversely, sidedness was no longer signiﬁcant, again
possibly because of the low number of right-sided tumors.
Consistent with the literature,13,19 MSI-high status was
associated with poor PFS outcome at the univariable
analysis, although the number of MSI-high occurrences in
this data set was quite small (only ﬁve patients) and did not
allow us to properly assess its independent prognostic
role. The type of maintenance treatment retained its value
in terms of PFS but not OS; this result has been already
reported11 and may be due to the low number of OS events
at the time of data cutoff and to the underpowered
sample size.
Interestingly, we observed that ORR and depth of response
were numerically increased in patients with right-sided/
PRESSING-negative versus right-sided/PRESSING-positive
tumors. A similar role of the PRESSING panel was observed
in the left-sided subgroup. However, in the speciﬁc sub-
group of patients with right-sided tumors, the increase of
response rate achieved thanks to negative hyperselection
failed to translate into a beneﬁt in terms of duration of
response, PFS, or OS. This is in line with post hoc analyses
of pivotal trials and meta-analyses that investigated the
impact of sidedness on ORR versus survival end points in
patients with RAS wild-type mCRC who received anti-
EGFR–based treatment.8,20,21 On the basis of such results,
an anti-EGFR–based ﬁrst-line treatment rarely may be
offered on an individual basis to patients with right-sided
RAS wild-type mCRC, at least whenever tumor response is
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FIG 3. Predictive analysis according to tumor sidedness and primary resistance in RAS andBRAF wild-typemetastatic colorectal
cancer patients treated with anti-EGFR monoclonal antibodies (PRESSING) panel status: Kaplan-Meier curves for (A)
progression-free survival (PFS) and (B) overall survival (OS) in patients stratiﬁed according to the two different maintenance
treatment arms and sidedness (right- v left-sided tumors) and for (C) PFS and (D) OS according to treatment arm and PRESSING
panel status (positive [pos] v negative [neg]).
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the primary goal of treatment and particularly when anti-
angiogenics and/or triplet chemotherapy are contra-
indicated. Given the higher prevalence of PRESSING panel
alterations in right-sided tumors, the role of negative mo-
lecular hyperselection may be crucial for some patients
with RAS and BRAF wild-type/right-sided tumors.
Furthermore, the PFS beneﬁt of FU plus LV added to
panitumumab in the maintenance setting was independent
from sidedness and PRESSING panel status, which thus
conﬁrmed the crucial role of ﬂuoropyrimidine continuation
in the maintenance setting. However, PFS was extremely
poor in patients with right-sided or PRESSING-positive
disease treated with single-agent panitumumab, with an
abrupt decrease of the curves after 4 months (which
corresponded to the end of the induction phase). This
result highlights that single-agent anti-EGFRs should not
be regarded as an effective maintenance treatment strat-
egy in disease subgroups with a lack of clinically or mo-
lecularly deﬁned EGFR dependency. In these subgroups,
de-escalation to a fully chemotherapy-free maintenance
strategy was associated with a signiﬁcant loss of efﬁcacy,
and, in patients with right-sided mCRC (which is itself as-
sociated with poorer outcomes22), a detrimental effect was
observed even in terms of OS.
This study has some clear limitations. First of all, because
both maintenance treatment arms contained pan-
itumumab, we could not investigate the predictive role of
tumor sidedness and PRESSING panel status with regard
to anti-EGFR therapy. However, because FU plus LV was
administered only in arm A, we could identify a subgroup of
patients (ie, right-sided and/or PRESSING-positive disease)
who derived a limited beneﬁt from single-agent pan-
itumumab, which conﬁrmed the fundamental role of
chemotherapy for maintenance treatment and suggested
the limited clinical beneﬁt from anti-EGFR treatment itself in
these subsets. Most important, the results of this study
should be interpreted with caution, because the role of anti-
EGFR therapy added to FU/LV in the maintenance setting
is still not established by level I evidence. This is particu-
larly relevant in light of the current lack of comparison with
other evidence-based maintenance options that have
better long-term tolerability, such as FU plus LV with or
without bevacizumab. Ongoing studies, such as Panama
(ClinicalTrials.gov identiﬁer: NCT01991873) and FIRE-4
(ClinicalTrials.gov identiﬁer: NCT02934529), we hope will
address the still-unanswered questions with their adequate
randomized settings.
Also, we acknowledge that, although tumor sidedness is
a simple, clearly deﬁnable and homogeneous variable, the
PRESSING panel is a composite biomarker that includes
several genomic alterations. Therefore, each genomic al-
teration may constitute a single marker, endowed with
a potential differential prognostic and/or predictive effect,
and our results do not distinguish the relative contribution of
individual variables because of the extremely low preva-
lence of each. The complex molecular interactions of these
candidate genomic alterations in the neoplastic signaling
pathways and their low prevalences limit their formal val-
idation in prospective clinical studies or in post hoc ana-
lyses of randomized clinical trials as negative predictive
markers for response to EGFR-targeted therapies, and this
limitation may impair their implementation in the tumor
proﬁling work-up, even if many of them are validated
therapeutic targets.10,14-16,23-29 Regarding RAS mutations
with an MAF less than the 5% cutoff, which was validated
for negative selection of patients for anti-EGFRs, it is still
unclear whether mutations with low fractional abundance
simply mirror tumor heterogeneity that may be overcome by
novel techniques, such as liquid biopsy,30 or may be as-
sociated with the rapid onset of acquired resistance and
limited long-term PFS beneﬁt under the selective pressure
of anti-EGFR agents continued until disease progression
develops.31
In conclusion, even if patients with left-sided, RAS and
BRAF wild-type tumors currently are considered the opti-
mal candidates for EGFR inhibitors,3 a consistent pro-
portion of them achieve a signiﬁcantly inferior clinical
beneﬁt from upfront anti-EGFR–based regimens, particu-
larly after de-escalation to maintenance treatment with
single-agent anti-EGFRs. A negative molecular hyper-
selection with our PRESSING panel, added to the initial
assessment of sidedness andRAS/BRAFmutational status,
may help identify a subgroup of patients who will excep-
tionally beneﬁt from anti-EGFR–based initial therapy.
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APPENDIX Supplementary Methods
The primary resistance in RAS and BRAF wild-type metastatic co-
lorectal cancer patients treated with anti-EGFR monoclonal antibodies
(PRESSING) panel analysis was performed as previously described.10
Speciﬁcally, immunohistochemistry (IHC) for HER2/MET and dual-
color silver in situ hybridization (SISH) for both genes were carried out
and scored as described previously (Pietrantonio F, et al: Clin Cancer
Res 23: 2412-2422, 2017; Valtorta E, et al: Mod Pathol 28:1481-1491,
2015). In detail, IHC was performed on 3-mm formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue sections or on WiDr cytoclots. MET protein
expression was detected by a rabbit monoclonal anti-MET antibody
(dilution 1:200; clone SP44; Spring Bioscience, Pleasanton, CA) di-
rected against the synthetic peptide derived from the C terminus of
human MET that displayed membranous and/or cytoplasmic epitope.
HER2 expression analysis was performed using the HercepTest an-
tibody (Agilent; Santa Clara, CA) and automatically on the automated
Benchmark Ultrasystem (Ventana Medical Systems, Tucson, AZ)
using the Ventana 4B5 antibody according to the manufacturers’
instructions. Bright-ﬁeld dual-color SISH analysis was performed on 3-
mm FFPE tissue sections using the MET DNP Probe (Ventana Medical
Systems) along with the Chromosome 7 DIG Probe (Ventana Medical
Systems) on a BenchMark Ultra Platform (Ventana Medical Systems)
according to the manufacturer’s protocol. HER2 ampliﬁcation analysis
by SISH with a Ventana Medical Systems 4B5 Inform HER2 dual color
on the BenchMark Ultra system (Inform HER2 DNA dual-color assay;
Roche Tissue Diagnostics, Ventana Medical Systems). The scoring
and evaluation for in situ hybridization was performed by counting
HER2 and CEN17 signals from 100 nuclei per case. Nontumor tissue
(normal colonmucosa) was used as an internal negative control.HER2
gene ampliﬁcation was deﬁned as positive when theHER2/CEP17 ratio
was two or greater or the average number of HER2 signals per tumor
cell nucleus was more than 6, whereasMET ampliﬁcation was deﬁned
as positive when the MET/CEP7 ratio was two or greater or average
number of MET signals per tumor cell nucleus was more than 6.
IHC for ALK/ROS1/panTRK/RET was carried out as screening method
using standard protocols for pan-Trk (including TrkA, TrkB, TrkC; Cell
Signaling, Danvers, MA; clone C17F1, 1:25 dilution), ROS1 (Cell
Signaling; clone D4D6, 1:500 dilution), ALK (Cell Signaling, Danvers,
MA; clone D5F3, 1:500 dilution) and RET (Abcam, Cambridge, United
Kingdom; clone EPR2871). In all samples with evidence of IHC
staining of any intensity/extension, whole-transcriptome shotgun se-
quencing (RNA-seq) was performed to conﬁrm the presence of
speciﬁc rearrangements and to identify the speciﬁc fusion partner.14
Mutational analysis was performed on FFPE specimens for each case;
these were sliced in 5-mm sections and manually microdissected to
isolate the tumor area that carried the highest percentage of neoplastic
cells—identiﬁed by a pathologist on hematoxylin and eosin. A minimal
tumor percentage of 10% was required; the average tumor percentage
was 70% (range, 10% to 90%), and no difference of percentages was
observed between sensitive and resistant samples. Samples were
treated with xylene and 100% ethanol to remove parafﬁn, and then
DNA was isolated using the GeneRead DNA FFPE kit (catalog No.
180134; Qiagen, Hilden, Germany; ). DNA amount and quality were
identiﬁed using Nano Drop platform and Qbit dsDNA BR kit (Ther-
moFisher Scientiﬁc, Waltham, MA) according to the manufacturer’s
instructions. Oncogenic mutations in the hotspot regions of 50 on-
cogenes and tumor suppressor genes commonly mutated in human
cancers (Cancer Hotspot Panel v2, ThermoFisher Scientiﬁc: ABL1,
AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1,
EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3,
FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2,
JAK3, KDR/VEGFR2, KIT, KRAS,MET,MLH1,MPL, NOTCH1, NPM1,
NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4,
SMARCB1, SMO, SRC, STK11, TP53, VHL) were assessed by means
of targeted next-generation sequencing through the Ion Torrent Per-
sonal Genome platform (ThermoFisher Scientiﬁc) , according to the
manufacturer’s instructions (Peitrantonio F, et al: Ann Oncol 27:2097-
2103, 2016; Pietrantonio F, et al: Clin Cancer Res 24:1082-1089,
2018).
The BRAF and RAS mutational status was centrally reassessed
through targeted next-generation sequencing with deeper coverage to
detect low-percentage and atypical RAS mutations. The fractional
abundances of BRAF and RAS mutations, called mutant allele frac-
tions (MAFs) were reported. Average sequencing depth was 1,0003,
and mutations were deﬁned with a minimum MAF of 3%. MAF was
corrected for tumor cellularity, deﬁned as the percentage of tissue
sample occupied by tumor cells on the total amount of cells, including
stromal microenvironment and inﬂammatory inﬁltrate.12
Microsatellite instability status (MSI) analysis was performed after DNA
was extracted from each tumor block and ampliﬁed via polymerase
chain reaction. The MSI status was identiﬁed using ﬁve quasi-
monomorphic mononucleotide markers able to provide highly accu-
rate determinations of the tumor MSI status from DNA: BAT-25, BAT-26,
NR-21, NR-24, and MONO-27 (MSI Analysis System, version 1.2;
Promega, Madison, WI). According to previous evidence, cases with
instability at two or more of the ﬁvemarkers were classiﬁed asMSI high,
whereas samples with instability at one marker and without instability
were categorized as MSI low and microsatellite stable, respectively
(Smyth EC, et al: JAMA Oncol 3:1197-1203, 2017).
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FIG A1. CONSORT diagram of the study.
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FIG A6. Predictive analysis according to combined tumor sidedness and primary resistance in RAS and BRAF wild-type
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TABLE A1. Incidence of the Singular Molecular Alterations Included in the PRESSING Panel
No. Patient ID Site of the Sample PRESSING Panel Alterations (% of tumor cells)
RAS Adjusted
MAF
01 001-001 M WT WT
02 001-002 M WT WT
03 001-003 P PIK3CA exon 20 mutation: A1035V (32), MSI WT
04 001-004 M WT WT
05 001-005 P WT WT
06 001-006 P MET ampliﬁcation (100) WT
07 001-007 P WT WT
08 001-008 P WT WT
09 001-009 P WT WT
10 001-011 M MSI WT
11 001-012 M WT WT
12 001-013 M WT WT
13 001-014 M WT WT
14 001-016 M AKT1 exon 2 mutation: A50T (16) WT
15 001-017 P WT WT
16 001-018 P WT WT
17 001-019 M WT WT
18 001-020 P WT WT
19 001-021 P WT WT
20 001-022 P WT WT
21 001-023 P WT WT
22 001-024 P RET rearrangement (20) 1%
KRAS exon 2 mutation: G12D
23 001-025 P WT WT
24 001-026 P WT WT
25 001-028 P KRAS exon 2 mutation: G12V 10%
26 001-029 P WT WT
27 001-030 M WT WT
28 001-031 B KRAS exon 2 mutation: G12D 7%
29 001-032 M WT WT
30 001-033 P WT WT
31 001-034 M WT WT
32 001-036 P PTEN mutation: delP248 exon 7 (25); delT321 exon 8 (29) WT
MSI
33 001-037 P WT WT
34 001-038 P WT WT
35 001-039 P WT WT
36 001-040 P PTEN exon 5 mutation: K128N (36) WT
37 001-041 M WT WT
38 001-043 P WT WT
39 001-044 M HER2 ampliﬁcation WT
40 001-045 P WT WT
41 001-046 P WT WT
(continued on following page)
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TABLE A1. Incidence of the Singular Molecular Alterations Included in the PRESSING Panel (continued)
No. Patient ID Site of the Sample PRESSING Panel Alterations (% of tumor cells)
RAS Adjusted
MAF
42 001-047 P WT WT
43 001-048 P WT WT
44 002-001 M WT WT
45 002-002 B NRAS exon 3 mutation: Q61R 1%
KRAS exon 2 mutation: G12V 4%
46 003-001 P WT WT
47 003-002 P WT WT
48 003-003 P WT WT
49 003-004 P WT WT
50 003-005 P WT WT
51 003-006 P HER2 ampliﬁcation WT
52 003-007 P WT WT
53 003-008 P WT WT
54 004-001 P WT WT
55 004-002 P WT WT
56 004-004 P WT WT
57 004-005 M WT WT
58 004-007 P WT WT
59 004-008 P WT WT
60 004-009 P NTRK rearrangement (EML4-NTRK3) WT
61 004-010 P WT WT
62 004-012 P WT WT
63 004-013 P PIK3CA exon 20 mutation: H1047L (80) WT
64 004-014 P WT WT
65 004-015 P WT WT
66 004-016 P WT WT
67 004-017 P WT WT
68 004-018 P WT WT
69 004-019 P WT WT
70 004-020 P WT WT
71 004-021 P WT WT
72 004-022 P PTEN exon 7 mutation: C250V-fsTer 5 (39) WT
73 004-024 P WT WT
74 004-025 P PIK3CA exon 20 mutation –H1047L (38) WT
75 004-026 P WT WT
76 004-027 P WT WT
77 004-028 P WT WT
78 004-029 P WT WT
79 004-030 P WT WT
80 004-031 P WT WT
81 004-033 P WT WT
82 005-001 P WT WT
83 005-002 P MET ampliﬁcation (53) WT
(continued on following page)
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TABLE A1. Incidence of the Singular Molecular Alterations Included in the PRESSING Panel (continued)
No. Patient ID Site of the Sample PRESSING Panel Alterations (% of tumor cells)
RAS Adjusted
MAF
84 005-004 P WT WT
85 005-006 P MET ampliﬁcation (83) WT
HER2 ampliﬁcation
86 005-009 P WT WT
87 006-001 P WT WT
88 006-003 P WT WT
89 006-004 P KRAS exon 2 mutation: G12S 1%
90 007-001 P WT WT
91 007-002 P WT WT
92 007-005 M WT WT
93 007-006 P WT WT
94 007-007 P WT WT
95 007-008 P MSI WT
96 007-009 P WT WT
97 007-010 P PTEN exon 5 mutation: R130G (15) WT
98 007-011 P WT WT
99 007-012 P WT WT
100 007-013 P WT WT
101 007-014 P HER2 ampliﬁcation WT
102 007-015 P HER2 ampliﬁcation WT
103 008-001 P WT WT
104 008-002 P WT WT
105 008-003 P WT WT
106 008-004 M NRAS exon 2 mutation: G13S 3%
107 008-005 M WT WT
108 008-006 P WT WT
109 008-007 P KRAS exon 2 mutation: G12D 1%
110 008-008 P PIK3CA exon 20 mutation: H1047R (5) WT
111 008-009 P PIK3CA exon 20 mutation: H1047R (70) WT
112 008-010 P WT WT
113 008-011 P WT WT
114 008-012 B WT WT
115 008-013 M WT WT
116 008-014 P WT WT
117 008-015 P WT WT
118 008-016 P PIK3CA exon 20 mutation: H1047L (30) WT
119 009-001 M HER2 ampliﬁcation WT
120 009-002 P WT WT
121 010-001 M WT WT
122 010-002 P WT WT
123 010-003 P WT WT
124 010-004 M WT WT
125 010-005 P HER2 ampliﬁcation WT
(continued on following page)
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TABLE A1. Incidence of the Singular Molecular Alterations Included in the PRESSING Panel (continued)
No. Patient ID Site of the Sample PRESSING Panel Alterations (% of tumor cells)
RAS Adjusted
MAF
126 011-001 P WT WT
127 011-002 P RET rearrangement (50) WT
128 011-003 M WT WT
129 011-004 P WT WT
130 011-005 P WT WT
131 011-006 P WT WT
132 011-007 P KRAS exon 2 mutation: G12D 1%
133 012-001 P WT WT
134 012-002 P RET rearrangement WT
135 012-003 P WT WT
136 012-004 P WT WT
137 012-005 P HER2 ampliﬁcation WT
138 012-006 P NRAS exon 2 mutation: G12C 3%
139 012-007 P WT WT
140 012-008 P WT WT
141 013-001 P WT WT
142 013-002 M WT WT
143 013-003 M WT WT
144 013-004 P PTEN exon 5 mutation: H118L (30) WT
145 013-005 P WT WT
146 013-006 P WT WT
147 013-007 P WT WT
148 015-002 P WT WT
149 015-003 P KRAS exon 2 mutation: G12D 1%
150 015-004 M WT WT
151 015-005 M WT WT
152 015-006 P KRAS exon 2 mutation: G13S 1%
153 015-007 M WT WT
154 015-008 P PIK3CA exon 20 mutation: D1045V (9); H1047R (8) WT
155 016-001 P WT WT
156 016-002 P WT WT
157 017-001 P PTEN mutation: c.635-1G.C atypical RAS mutation L19F NA
158 017-003 P WT WT
159 017-004 B WT WT
160 017-005 P HER2 ampliﬁcation WT
161 018-001 P PIK3CA exon 20 mutation: H1047R (21) WT
162 018-003 M WT WT
163 018-004 P PIK3CA exon 20 mutation: Q546K (19) WT
164 018-006 P WT WT
165 019-002 P WT WT
166 019-003 M WT WT
167 020-001 P WT WT
168 020-002 P WT WT
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TABLE A1. Incidence of the Singular Molecular Alterations Included in the PRESSING Panel (continued)
No. Patient ID Site of the Sample PRESSING Panel Alterations (% of tumor cells)
RAS Adjusted
MAF
169 020-003 P WT WT
170 020-005 P WT WT
171 020-006 P WT WT
172 020-007 P WT WT
173 020-008 P WT WT
174 020-009 M WT WT
175 021-001 M WT WT
176 021-002 P ALK rearrangement (50) WT
177 021-003 B WT WT
178 023-001 P WT WT
179 024-001 M PIK3CA exon 20 mutation: H1047R (32)
4%KRAS exon 2 mutation: G12D
180 024-002 P WT WT
181 024-003 P AKT1 exon 2 mutation: D46E (58) WT
182 025-001 P MSI WT
183 025-002 P KRAS exon 3 mutation: Q61H 2%
184 025-003 P WT WT
185 025-004 P WT WT
186 025-005 M WT WT
187 025-006 M WT WT
188 025-007 M WT WT
189 026-001 P WT WT
190 026-002 P KRAS exon 2 mutation: G12V 3%
191 026-003 P WT WT
192 026-004 M WT WT
193 027-002 P WT WT
194 027-003 M WT WT
195 027-005 P WT WT
196 028-002 P WT WT
197 029-002 P WT WT
198 030-001 P WT WT
199 030-002 P WT WT
Abbreviations: B, both metastasis and primary tumor; M, metastasis; MAF, mutant allele fraction; MSI, microsatellite instability; NA, not
assessable; P, primary tumor; PRESSING, primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with
anti-EGFR monoclonal antibodies; WT, wild-type.
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TABLE A2. Individual Molecular Alterations, Primary Tumor Sidedness and Best RECIST Response to Induction Treatment in the Patients With
PRESSING Panel–Positive or Right-Sided Primary Tumors
No. Patient ID PRESSING Panel Alteration (%) Primary Tumor Sidedness Best Response
01 001-003 PIK3CA exon 20 mutation: A1035V (32) MSI Left SD
02 001-004 WT Right SD
03 001-006 MET ampliﬁcation (100) Left PR
04 001-009 WT Right SD
05 001-011 MSI Left SD
06 001-016 AKT1 exon 2 mutation: A50T (16) Right PR
07 001-020 WT Right NE
08 001-024 RET rearrangement (20%) Left PR
KRAS exon 2 mutation: G12D (1)
09 001-028 KRAS exon 2 mutation: G12V (10) Left SD
10 001-031 KRAS exon 2 mutation: G12D (7) Left PR
11 001-036 PTEN mutation: delP248 exon 7 (25) Left PD
delT321 exon 8 (29%); MSI
12 001-037 WT Right CR
13 001-040 PTEN exon 5 mutation: K128N (36) Right SD
14 001-044 HER2 ampliﬁcation Left PR
15 002-002 NRAS exon 3 mutation: Q61R (1) Right PD
KRAS exon 2 mutation: G12V (4)
16 003-006 HER2 ampliﬁcation Left PR
17 004-009 NTRK rearrangement (EML4-NTRK3) Right SD
18 004-013 PIK3CA exon 20 mutation: H1047L (80) Left SD
19 004-022 PTEN exon 7 mutation: C250V-fsTer 5 (39) Left CR
20 004-025 PIK3CA exon 20 mutation: H1047L (38) Left PR
21 004-027 WT Right PR
22 005-002 MET ampliﬁcation (53) Left PR
23 005-006 MET ampliﬁcation (83); HER2 ampliﬁcation Left PR
24 006-004 KRAS exon 2 mutation: G12S (1) Left NE
25 007-005 WT Right NE
26 007-008 MSI Left PR
27 007-010 PTEN exon 5 mutation: R130G (15) Left PR
28 007-011 WT Right PR
29 007-014 HER2 ampliﬁcation Left PR
30 007-015 HER2 ampliﬁcation Left PR
31 008-002 WT Right PD
32 008-004 NRAS exon 2 mutation: G13S (3) Left SD
33 008-006 WT Right NE
34 008-007 KRAS exon 2 mutation: G12D (1) Left PR
35 008-008 PIK3CA exon 20 mutation: H1047R (5) Left PR
36 008-009 PIK3CA exon 20 mutation: H1047R (70) Left PR
37 008-016 PIK3CA exon 20 mutation: H1047L (30) Left SD
38 009-001 HER2 ampliﬁcation Left SD
39 010-005 HER2 ampliﬁcation Left PR
40 011-002 RET rearrangement (50) Left SD
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TABLE A2. Individual Molecular Alterations, Primary Tumor Sidedness and Best RECIST Response to Induction Treatment in the Patients With
PRESSING Panel–Positive or Right-Sided Primary Tumors (continued)
No. Patient ID PRESSING Panel Alteration (%) Primary Tumor Sidedness Best Response
41 011-007 KRAS exon 2 mutation: G12D (1) Left PR
42 012-001 WT Right PR
43 012-002 RET rearrangement Right PD
44 012-005 HER2 ampliﬁcation Left PR
45 012-006 NRAS exon 2 mutation: G12C (3) Left SD
46 013-002 WT Right PR
47 013-004 PTEN exon 5 mutation: H118L (30) Right PR
48 0015-003 KRAS exon 2 mutation: G12D (1) Left CR
49 0015-004 WT Right NE
50 0015-006 KRAS exon 2 mutation: G13S (1) Left SD
51 0015-008 PIK3CA exon 20 mutation: D1045V (9) Left CR
H1047R (8)
52 0017-001 PTEN mutation: c.635-1G.C Left PR
atypical RAS mutation L19F
53 0017-005 HER2 ampliﬁcation Right PR
54 0018-001 PIK3CA exon 20 mutation: H1047R (21) Left PR
55 0018-004 PIK3CA exon 20 mutation: Q546K (19) Left PR
56 0019-003 WT Right PR
57 0020-002 WT Right PR
58 0020-003 WT Right PR
59 0020-007 WT Right PR
60 0021-002 ALK rearrangement (50) Right PR
61 0021-003 WT Right PR
62 0024-001 PIK3CA exon 20 mutation: H1047R (32) Left PD
KRAS exon 2 mutation: G12D (4)
63 0024-003 AKT1 exon 2 mutation: D46E (58) Right PR
64 0025-001 MSI Right NE
65 0025-002 KRAS exon 3 mutation: Q61H (2) Left NE
66 0025-007 WT Right PR
67 0026-002 KRAS exon 2 mutation: G12V (3) Right PD
Abbreviations: CR, complete response; MSI, microsatellite instability; NE, not evaluated (nonmeasurable disease or patients with clinical
disease progression prior to the ﬁrst tumor reassessment); PD, progressive disease; PR, partial response; PRESSING, primary resistance in RAS
and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies; SD, stable disease; WT, wild type.
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TABLE A3. Depth of Response to Induction Treatment With
Panitumumab Plus FOLFOX-4 According to Sidedness, PRESSING
Panel or Both
Variable
Depth of Response (%)
P*Median IQR
Overall population 244.7 259.8 to 219.8 —
Arm .998
A (FU + LV + panitumumab) 244.7 259.2 to 221.2
B (panitumumab) 244.7 260.2 to 216.8
Sidedness .114
Left 244.8 260.1 to 224.2
Right 236.0 254.4 to 21.0
PRESSING panel .017
Negative 246.9 262.1 to 230.2
Positive 238.8 251.3 to 7.5
Left-sided subgroup .062
PRESSING negative 246.9 262.4 to 231.1
PRESSING positive 239.6 252.5 to 213.6
Right-sided subgroup .230
PRESSING negative 248.2 259.2 to 8.3
PRESSING positive 220.0 246.7 to 21.0
Abbreviations: FU + LV, ﬂuorouracil plus leucovorin; IQR,
interquartile range; PRESSING, primary resistance in RAS and BRAF
wild-type metastatic colorectal cancer patients treated with anti-EGFR
monoclonal antibodies.
*Wilcoxon test.
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